353 reports of this reaction
3.1% of all LOTEPREDNOL ETABONATE reports
#6 most reported adverse reaction
OCULAR HYPERAEMIA is the #6 most commonly reported adverse reaction for LOTEPREDNOL ETABONATE, manufactured by Bausch & Lomb Incorporated. There are 353 FDA adverse event reports linking LOTEPREDNOL ETABONATE to OCULAR HYPERAEMIA. This represents approximately 3.1% of all 11,509 adverse event reports for this drug.
Patients taking LOTEPREDNOL ETABONATE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among LOTEPREDNOL ETABONATE users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for LOTEPREDNOL ETABONATE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 353 FDA reports for LOTEPREDNOL ETABONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 3.1% of all adverse event reports for LOTEPREDNOL ETABONATE, making it a notable side effect.
If you experience ocular hyperaemia while taking LOTEPREDNOL ETABONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.